{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T05:35:51Z","timestamp":1776231351739,"version":"3.50.1"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,1,13]],"date-time":"2017-01-13T00:00:00Z","timestamp":1484265600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2017,1,13]],"date-time":"2017-01-13T00:00:00Z","timestamp":1484265600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P20CA192987"],"award-info":[{"award-number":["P20CA192987"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1186\/s12885-016-3034-2","type":"journal-article","created":{"date-parts":[[2017,1,13]],"date-time":"2017-01-13T10:02:23Z","timestamp":1484301743000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Evaluation of the cytotoxicity of the Bithionol - cisplatin combination in a panel of human ovarian cancer cell lines"],"prefix":"10.1186","volume":"17","author":[{"given":"Vijayalakshmi N.","family":"Ayyagari","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsung-han Jeff","family":"Hsieh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paula L.","family":"Diaz-Sylvester","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurent","family":"Brard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,1,13]]},"reference":[{"issue":"5","key":"3034_CR1","doi-asserted-by":"publisher","first-page":"277","DOI":"10.3322\/caac.20073","volume":"60","author":"A Jemal","year":"2010","unstructured":"Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010;60(5):277\u2013300.","journal-title":"CA Cancer J Clin"},{"issue":"6","key":"3034_CR2","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1007\/s11912-006-0074-9","volume":"8","author":"TJ Herzog","year":"2006","unstructured":"Herzog TJ. The current treatment of recurrent ovarian cancer. Curr Oncol Rep. 2006;8(6):448\u201354.","journal-title":"Curr Oncol Rep"},{"issue":"7","key":"3034_CR3","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1038\/nrc1123","volume":"3","author":"R Agarwal","year":"2003","unstructured":"Agarwal R, Kaye SB. Ovarian cancer: strategies for overcoming resistance to chemotherapy. Nat Rev Cancer. 2003;3(7):502\u201316.","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"3034_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1056\/NEJM199601043340101","volume":"334","author":"WP McGuire","year":"1996","unstructured":"McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Look KY, Clarke-Pearson DL, Davidson M. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med. 1996;334(1):1\u20136.","journal-title":"N Engl J Med"},{"issue":"9","key":"3034_CR5","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1093\/jnci\/92.9.699","volume":"92","author":"MJ Piccart","year":"2000","unstructured":"Piccart MJ, Bertelsen K, James K, Cassidy J, Mangioni C, Simonsen E, Stuart G, Kaye S, Vergote I, Blom R, et al. Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. J Natl Cancer Inst. 2000;92(9):699\u2013708.","journal-title":"J Natl Cancer Inst"},{"issue":"2","key":"3034_CR6","first-page":"115","volume":"14","author":"Y Kikuchi","year":"2001","unstructured":"Kikuchi Y. The mechanism of cisplatin-resistance in ovarian cancer. Hum Cell. 2001;14(2):115\u201333.","journal-title":"Hum Cell"},{"issue":"1","key":"3034_CR7","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/S0090-8258(03)00464-5","volume":"91","author":"MM Leitao","year":"2003","unstructured":"Leitao MM, Hummer A, Dizon DS, Aghajanian C, Hensley M, Sabbatini P, Venkatraman E, Spriggs DR. Platinum retreatment of platinum-resistant ovarian cancer after nonplatinum therapy. Gynecol Oncol. 2003;91(1):123\u20139.","journal-title":"Gynecol Oncol"},{"issue":"5","key":"3034_CR8","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1111\/j.1048-891X.2004.014507.x","volume":"14","author":"HE Lambert","year":"2004","unstructured":"Lambert HE, Gregory WM, Nelstrop AE, Rustin GJ. Long-term survival in 463 women treated with platinum analogs for advanced epithelial carcinoma of the ovary: life expectancy compared to women of an age-matched normal population. Int J Gynecol Cancer. 2004;14(5):772\u20138.","journal-title":"Int J Gynecol Cancer"},{"issue":"3","key":"3034_CR9","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1002\/ardp.200600151","volume":"340","author":"I Ott","year":"2007","unstructured":"Ott I, Gust R. Non platinum metal complexes as anti-cancer drugs. Arch Pharm (Weinheim). 2007;340(3):117\u201326.","journal-title":"Arch Pharm (Weinheim)"},{"issue":"11","key":"3034_CR10","doi-asserted-by":"publisher","first-page":"1339","DOI":"10.1517\/13543784.2010.515585","volume":"19","author":"K Matsuo","year":"2010","unstructured":"Matsuo K, Lin YG, Roman LD, Sood AK. Overcoming platinum resistance in ovarian carcinoma. Expert Opin Investig Drugs. 2010;19(11):1339\u201354.","journal-title":"Expert Opin Investig Drugs"},{"issue":"15","key":"3034_CR11","doi-asserted-by":"publisher","first-page":"1869","DOI":"10.1038\/onc.2011.384","volume":"31","author":"L Galluzzi","year":"2012","unstructured":"Galluzzi L, Senovilla L, Vitale I, Michels J, Martins I, Kepp O, Castedo M, Kroemer G. Molecular mechanisms of cisplatin resistance. Oncogene. 2012;31(15):1869\u201383.","journal-title":"Oncogene"},{"issue":"9","key":"3034_CR12","doi-asserted-by":"publisher","first-page":"2467","DOI":"10.1021\/cr980421n","volume":"99","author":"ER Jamieson","year":"1999","unstructured":"Jamieson ER, Lippard SJ. Structure, Recognition, and Processing of Cisplatin-DNA Adducts. Chem Rev. 1999;99(9):2467\u201398.","journal-title":"Chem Rev"},{"key":"3034_CR13","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/S0079-6603(01)67026-0","volume":"67","author":"SM Cohen","year":"2001","unstructured":"Cohen SM, Lippard SJ. Cisplatin: from DNA damage to cancer chemotherapy. Prog Nucleic Acid Res Mol Biol. 2001;67:93\u2013130.","journal-title":"Prog Nucleic Acid Res Mol Biol"},{"issue":"3","key":"3034_CR14","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.cbi.2004.03.001","volume":"147","author":"K Wozniak","year":"2004","unstructured":"Wozniak K, Czechowska A, Blasiak J. Cisplatin-evoked DNA fragmentation in normal and cancer cells and its modulation by free radical scavengers and the tyrosine kinase inhibitor STI571. Chem Biol Interact. 2004;147(3):309\u201318.","journal-title":"Chem Biol Interact"},{"issue":"1","key":"3034_CR15","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.ejphar.2010.09.085","volume":"650","author":"E-S El-Awady","year":"2011","unstructured":"El-Awady E-S, Moustafa YM, Abo-Elmatty DM, Radwan A. Cisplatin-induced cardiotoxicity: Mechanisms and cardioprotective strategies. Eur J Pharmacol. 2011;650(1):335\u201341.","journal-title":"Eur J Pharmacol"},{"issue":"8","key":"3034_CR16","doi-asserted-by":"publisher","first-page":"BR179","DOI":"10.12659\/MSM.881894","volume":"17","author":"G Lorito","year":"2011","unstructured":"Lorito G, Hatzopoulos S, Laurell G, Campbell KC, Petruccelli J, Giordano P, Kochanek K, Sliwa L, Martini A, Skarzynski H. Dose-dependent protection on cisplatin-induced ototoxicity - an electrophysiological study on the effect of three antioxidants in the Sprague-Dawley rat animal model. Med Sci Monit. 2011;17(8):BR179\u2013186.","journal-title":"Med Sci Monit"},{"issue":"7","key":"3034_CR17","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1258\/ebm.2011.011096","volume":"236","author":"RN Donahue","year":"2011","unstructured":"Donahue RN, McLaughlin PJ, Zagon IS. Low-dose naltrexone suppresses ovarian cancer and exhibits enhanced inhibition in combination with cisplatin. Exp Biol Med (Maywood). 2011;236(7):883\u201395.","journal-title":"Exp Biol Med (Maywood)"},{"issue":"3","key":"3034_CR18","doi-asserted-by":"publisher","first-page":"124","DOI":"10.3766\/jaaa.14.3.2","volume":"14","author":"KC Campbell","year":"2003","unstructured":"Campbell KC, Larsen DL, Meech RP, Rybak LP, Hughes LF. Glutathione ester but not glutathione protects against cisplatin-induced ototoxicity in a rat model. J Am Acad Audiol. 2003;14(3):124\u201333.","journal-title":"J Am Acad Audiol"},{"issue":"3","key":"3034_CR19","doi-asserted-by":"publisher","first-page":"410","DOI":"10.5301\/jn.5000018","volume":"25","author":"M Nematbakhsh","year":"2012","unstructured":"Nematbakhsh M, Ashrafi F, Safari T, Talebi A, Nasri H, Mortazavi M, Khazaei M, Baradaran-Mahdavi MM. Administration of vitamin E and losartan as prophylaxes in cisplatin-induced nephrotoxicity model in rats. J Nephrol. 2012;25(3):410\u20137.","journal-title":"J Nephrol"},{"issue":"10","key":"3034_CR20","doi-asserted-by":"publisher","first-page":"655","DOI":"10.3109\/00207454.2010.510916","volume":"120","author":"S Tuncer","year":"2010","unstructured":"Tuncer S, Dalkilic N, Akif Dunbar M, Keles B. Comparative effects of \u03b1 lipoic acid and melatonin on cisplatin-induced neurotoxicity. Int J Neurosci. 2010;120(10):655\u201363.","journal-title":"Int J Neurosci"},{"issue":"11","key":"3034_CR21","doi-asserted-by":"publisher","first-page":"3484","DOI":"10.1093\/ndt\/gfr195","volume":"26","author":"PD Sanchez-Gonzalez","year":"2011","unstructured":"Sanchez-Gonzalez PD, Lopez-Hernandez FJ, Perez-Barriocanal F, Morales AI, Lopez-Novoa JM. Quercetin reduces cisplatin nephrotoxicity in rats without compromising its anti-tumour activity. Nephrol Dial Transplant. 2011;26(11):3484\u201395.","journal-title":"Nephrol Dial Transplant"},{"issue":"3","key":"3034_CR22","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1016\/j.ygyno.2011.02.021","volume":"121","author":"A Yasmeen","year":"2011","unstructured":"Yasmeen A, Beauchamp MC, Piura E, Segal E, Pollak M, Gotlieb WH. Induction of apoptosis by metformin in epithelial ovarian cancer: involvement of the Bcl-2 family proteins. Gynecol Oncol. 2011;121(3):492\u20138.","journal-title":"Gynecol Oncol"},{"issue":"5","key":"3034_CR23","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1593\/neo.11148","volume":"13","author":"R Rattan","year":"2011","unstructured":"Rattan R, Graham RP, Maguire JL, Giri S, Shridhar V. Metformin suppresses ovarian cancer growth and metastasis with enhancement of cisplatin cytotoxicity in vivo. Neoplasia. 2011;13(5):483\u201391.","journal-title":"Neoplasia"},{"issue":"3","key":"3034_CR24","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/j.jep.2006.03.024","volume":"107","author":"HH Yu","year":"2006","unstructured":"Yu HH, Seo SJ, Kim YH, Lee HY, Park RK, So HS, Jang SL, You YO. Protective effect of Rehmannia glutinosa on the cisplatin-induced damage of HEI-OC1 auditory cells through scavenging free radicals. J Ethnopharmacol. 2006;107(3):383\u20138.","journal-title":"J Ethnopharmacol"},{"issue":"6","key":"3034_CR25","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1002\/hep.1840140620","volume":"14","author":"Y Bacq","year":"1991","unstructured":"Bacq Y, Besnier JM, Duong TH, Pavie G, Metman EH, Choutet P. Successful treatment of acute fascioliasis with bithionol. Hepatology. 1991;14(6):1066\u20139.","journal-title":"Hepatology"},{"key":"3034_CR26","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/1471-2407-14-61","volume":"14","author":"VN Ayyagari","year":"2014","unstructured":"Ayyagari VN, Brard L. Bithionol inhibits ovarian cancer cell growth in vitro - studies on mechanism(s) of action. BMC Cancer. 2014;14:61.","journal-title":"BMC Cancer"},{"issue":"6","key":"3034_CR27","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1097\/CAD.0000000000000364","volume":"27","author":"VN Ayyagari","year":"2016","unstructured":"Ayyagari VN, Johnston NA, Brard L. Assessment of the antitumor potential of Bithionol in vivo using a xenograft model of ovarian cancer. Anticancer Drugs. 2016;27(6):547\u201359.","journal-title":"Anticancer Drugs"},{"issue":"2","key":"3034_CR28","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1158\/0008-5472.CAN-09-1947","volume":"70","author":"TC Chou","year":"2010","unstructured":"Chou TC. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res. 2010;70(2):440\u20136.","journal-title":"Cancer Res"},{"key":"3034_CR29","doi-asserted-by":"crossref","unstructured":"Kasibhatla S, Amarante-Mendes GP, Finucane D, Brunner T, Bossy-Wetzel E, Green DR. Detection of phosphatidylserine externalization during apoptosis. CSH Protoc. 2006(3): pii: pdb.prot4494.","DOI":"10.1101\/pdb.prot4495"},{"issue":"11","key":"3034_CR30","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.2165\/11591720-000000000-00000","volume":"71","author":"RW Naumann","year":"2011","unstructured":"Naumann RW, Coleman RL. Management strategies for recurrent platinum-resistant ovarian cancer. Drugs. 2011;71(11):1397\u2013412.","journal-title":"Drugs"},{"issue":"5665","key":"3034_CR31","doi-asserted-by":"publisher","first-page":"1818","DOI":"10.1126\/science.1095833","volume":"303","author":"TM Allen","year":"2004","unstructured":"Allen TM, Cullis PR. Drug delivery systems: entering the mainstream. Science. 2004;303(5665):1818\u201322.","journal-title":"Science"},{"issue":"2","key":"3034_CR32","doi-asserted-by":"publisher","first-page":"E128","DOI":"10.1208\/aapsj0902015","volume":"9","author":"VP Torchilin","year":"2007","unstructured":"Torchilin VP. Targeted pharmaceutical nanocarriers for cancer therapy and imaging. AAPS J. 2007;9(2):E128\u2013147.","journal-title":"AAPS J"},{"issue":"10","key":"3034_CR33","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1038\/nm1001-1111","volume":"7","author":"PM Hwang","year":"2001","unstructured":"Hwang PM, Bunz F, Yu J, Rago C, Chan TA, Murphy MP, Kelso GF, Smith RA, Kinzler KW, Vogelstein B. Ferredoxin reductase affects p53-dependent, 5-fluorouracil-induced apoptosis in colorectal cancer cells. Nat Med. 2001;7(10):1111\u20137.","journal-title":"Nat Med"},{"issue":"1","key":"3034_CR34","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.ygyno.2011.03.035","volume":"122","author":"KK Kim","year":"2011","unstructured":"Kim KK, Kawar NM, Singh RK, Lange TS, Brard L, Moore RG. Tetrathiomolybdate induces doxorubicin sensitivity in resistant tumor cell lines. Gynecol Oncol. 2011;122(1):183\u20139.","journal-title":"Gynecol Oncol"},{"key":"3034_CR35","volume-title":"Small molecule inhibitors of autotaxin, and methods of use. Application WO2009151644 A2","author":"D Braddock","year":"2009","unstructured":"Braddock D. Small molecule inhibitors of autotaxin, and methods of use. Application WO2009151644 A2. USA: Yale University; 2009. This patent is notable as one of only two that include demonstration in vivo of anti- cancer activity of an ATX inhibitor."},{"issue":"10","key":"3034_CR36","doi-asserted-by":"publisher","first-page":"3352","DOI":"10.1158\/1535-7163.MCT-08-0463","volume":"7","author":"LP Saunders","year":"2008","unstructured":"Saunders LP, Ouellette A, Bandle R, Chang WC, Zhou H, Misra RN, De La Cruz EM, Braddock DT. Identification of small-molecule inhibitors of autotaxin that inhibit melanoma cell migration and invasion. Mol Cancer Ther. 2008;7(10):3352\u201362.","journal-title":"Mol Cancer Ther"},{"issue":"1","key":"3034_CR37","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1006\/excr.2000.4838","volume":"256","author":"SH Kaufmann","year":"2000","unstructured":"Kaufmann SH, Earnshaw WC. Induction of apoptosis by cancer chemotherapy. Exp Cell Res. 2000;256(1):42\u20139.","journal-title":"Exp Cell Res"},{"issue":"11","key":"3034_CR38","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1002\/1521-1878(200011)22:11<1007::AID-BIES7>3.0.CO;2-4","volume":"22","author":"SH Kaufmann","year":"2000","unstructured":"Kaufmann SH, Gores GJ. Apoptosis in cancer: cause and cure. Bioessays. 2000;22(11):1007\u201317.","journal-title":"Bioessays"},{"issue":"2","key":"3034_CR39","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1084\/jem.182.2.367","volume":"182","author":"N Zamzami","year":"1995","unstructured":"Zamzami N, Marchetti P, Castedo M, Decaudin D, Macho A, Hirsch T, Susin SA, Petit PX, Mignotte B, Kroemer G. Sequential reduction of mitochondrial transmembrane potential and generation of reactive oxygen species in early programmed cell death. J Exp Med. 1995;182(2):367\u201377.","journal-title":"J Exp Med"},{"issue":"2","key":"3034_CR40","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.bcp.2009.08.015","volume":"79","author":"L Liu","year":"2010","unstructured":"Liu L, Yang C, Herzog C, Seth R, Kaushal GP. Proteasome inhibitors prevent cisplatin-induced mitochondrial release of apoptosis-inducing factor and markedly ameliorate cisplatin nephrotoxicity. Biochem Pharmacol. 2010;79(2):137\u201346.","journal-title":"Biochem Pharmacol"},{"issue":"5","key":"3034_CR41","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1159\/000338302","volume":"35","author":"JJ Gao","year":"2012","unstructured":"Gao JJ, Cai GY, Ning YC, Liu L, Yang JR, Dong D, Fu B, Lu Y, Cui SY, Chen XM. DAP5 ameliorates cisplatin-induced apoptosis of renal tubular cells. Am J Nephrol. 2012;35(5):456\u201365.","journal-title":"Am J Nephrol"},{"issue":"7","key":"3034_CR42","first-page":"1217","volume":"11","author":"AG Eliopoulos","year":"1995","unstructured":"Eliopoulos AG, Kerr DJ, Herod J, Hodgkins L, Krajewski S, Reed JC, Young LS. The control of apoptosis and drug resistance in ovarian cancer: influence of p53 and Bcl-2. Oncogene. 1995;11(7):1217\u201328.","journal-title":"Oncogene"},{"issue":"9","key":"3034_CR43","first-page":"2178","volume":"56","author":"JJ Herod","year":"1996","unstructured":"Herod JJ, Eliopoulos AG, Warwick J, Niedobitek G, Young LS, Kerr DJ. The prognostic significance of Bcl-2 and p53 expression in ovarian carcinoma. Cancer Res. 1996;56(9):2178\u201384.","journal-title":"Cancer Res"},{"issue":"23","key":"3034_CR44","doi-asserted-by":"publisher","first-page":"7191","DOI":"10.1158\/1078-0432.CCR-07-0362","volume":"13","author":"J Witham","year":"2007","unstructured":"Witham J, Valenti MR, De-Haven-Brandon AK, Vidot S, Eccles SA, Kaye SB, Richardson A. The Bcl-2\/Bcl-XL family inhibitor ABT-737 sensitizes ovarian cancer cells to carboplatin. Clin Cancer Res. 2007;13(23):7191\u20138.","journal-title":"Clin Cancer Res"},{"issue":"6","key":"3034_CR45","doi-asserted-by":"crossref","first-page":"L1005","DOI":"10.1152\/ajplung.2000.279.6.L1005","volume":"279","author":"VJ Thannickal","year":"2000","unstructured":"Thannickal VJ, Fanburg BL. Reactive oxygen species in cell signaling. Am J Physiol Lung Cell Mol Physiol. 2000;279(6):L1005\u20131028.","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"issue":"7","key":"3034_CR46","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1038\/nrd2803","volume":"8","author":"D Trachootham","year":"2009","unstructured":"Trachootham D, Alexandre J, Huang P. Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach? Nat Rev Drug Discov. 2009;8(7):579\u201391.","journal-title":"Nat Rev Drug Discov"},{"issue":"3","key":"3034_CR47","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1002\/ijc.23158","volume":"122","author":"JS Kim","year":"2008","unstructured":"Kim JS, Lee JH, Jeong WW, Choi DH, Cha HJ, Kim DH, Kwon JK, Park SE, Park JH, Cho HR, et al. Reactive oxygen species-dependent EndoG release mediates cisplatin-induced caspase-independent apoptosis in human head and neck squamous carcinoma cells. Int J Cancer. 2008;122(3):672\u201380.","journal-title":"Int J Cancer"},{"issue":"5","key":"3034_CR48","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1124\/mol.56.5.867","volume":"56","author":"V Mansat-de Mas","year":"1999","unstructured":"Mansat-de Mas V, Bezombes C, Quillet-Mary A, Betta\u00efeb A, D\u2019orgeix AD, Laurent G, Jaffr\u00e9zou JP. Implication of radical oxygen species in ceramide generation, c-Jun N-terminal kinase activation and apoptosis induced by daunorubicin. Mol Pharmacol. 1999;56(5):867\u201374.","journal-title":"Mol Pharmacol"},{"issue":"1","key":"3034_CR49","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1093\/toxsci\/kfm087","volume":"98","author":"M Tsai-Turton","year":"2007","unstructured":"Tsai-Turton M, Luong BT, Tan Y, Luderer U. Cyclophosphamide-induced apoptosis in COV434 human granulosa cells involves oxidative stress and glutathione depletion. Toxicol Sci. 2007;98(1):216\u201330.","journal-title":"Toxicol Sci"},{"issue":"2","key":"3034_CR50","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1038\/tpj.2009.49","volume":"10","author":"AK Maiti","year":"2010","unstructured":"Maiti AK. Gene network analysis of oxidative stress-mediated drug sensitivity in resistant ovarian carcinoma cells. Pharmacogenomics J. 2010;10(2):94\u2013104.","journal-title":"Pharmacogenomics J"},{"issue":"4","key":"3034_CR51","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1016\/j.etp.2010.09.010","volume":"64","author":"A Meshkini","year":"2012","unstructured":"Meshkini A, Yazdanparast R. Involvement of oxidative stress in taxol-induced apoptosis in chronic myelogenous leukemia K562 cells. Exp Toxicol Pathol. 2012;64(4):357\u201365.","journal-title":"Exp Toxicol Pathol"},{"issue":"1","key":"3034_CR52","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1002\/ijc.22132","volume":"120","author":"M Berndtsson","year":"2007","unstructured":"Berndtsson M, H\u00e4gg M, Panaretakis T, Havelka AM, Shoshan MC, Linder S. Acute apoptosis by cisplatin requires induction of reactive oxygen species but is not associated with damage to nuclear DNA. Int J Cancer. 2007;120(1):175\u201380.","journal-title":"Int J Cancer"},{"issue":"19","key":"3034_CR53","first-page":"5390","volume":"60","author":"Y Mitsuuchi","year":"2000","unstructured":"Mitsuuchi Y, Johnson SW, Selvakumaran M, Williams SJ, Hamilton TC, Testa JR. The phosphatidylinositol 3-kinase\/AKT signal transduction pathway plays a critical role in the expression of p21WAF1\/CIP1\/SDI1 induced by cisplatin and paclitaxel. Cancer Res. 2000;60(19):5390\u20134.","journal-title":"Cancer Res"},{"issue":"11","key":"3034_CR54","doi-asserted-by":"publisher","first-page":"1514","DOI":"10.1038\/sj.bjc.6603448","volume":"95","author":"G He","year":"2006","unstructured":"He G, Kuang J, Huang Z, Koomen J, Kobayashi R, Khokhar AR, Siddik ZH. Upregulation of p27 and its inhibition of CDK2\/cyclin E activity following DNA damage by a novel platinum agent are dependent on the expression of p21. Br J Cancer. 2006;95(11):1514\u201324.","journal-title":"Br J Cancer"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-016-3034-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12885-016-3034-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-016-3034-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,14]],"date-time":"2020-05-14T13:06:07Z","timestamp":1589461567000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-016-3034-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1,13]]},"references-count":54,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["3034"],"URL":"https:\/\/doi.org\/10.1186\/s12885-016-3034-2","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,1,13]]},"assertion":[{"value":"22 July 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 December 2016","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 January 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"49"}}